Cure My Disease

Don't miss your cure!

 Log in / Sign up

New cell therapy combo targets childhood sarcomas in early trial

NCT ID NCT07222735

Recruiting now Disease control Sponsor: St. Jude Children's Research Hospital Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Jun 16, 2026 · Updated 34 times

Summary

This study tests a new treatment for children and young adults up to age 21 with sarcomas that have come back or not responded to standard therapy. It combines a special type of immune cell (B7-H3-CAR T cells) with targeted radiation to see if it is safe and can shrink tumors. About 42 participants will receive the therapy after chemotherapy to prepare their immune system.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OSTEOSARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • St. Jude Children's Research Hospital

    RECRUITING

    Memphis, Tennessee, 38105, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.

CHILDHOOD OSTEOSARCOMA CHILDHOOD RHABDOMYOSARCOMA CHILDHOOD SOFT TISSUE SARCOMA EWING SARCOMA EWING SARCOMA SARCOMA

Conditions inferred from the trial description

These were inferred from the trial's summary, not listed by the trial registrant.

OSTEOSARCOMA